China Monogenic Diabetes Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07492004

Acronym

CMDR

Enrollment

5000

Registered

2026-03-25

Start date

2021-02-28

Completion date

2030-07-31

Last updated

2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maturity Onset Diabetes of the Young, Monogenic Diabetes, Neonatal Diabetes

Keywords

Monogenic Diabetes, Neonatal Diabetes, Maturity Onset Diabetes of the Young

Brief summary

This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to: Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution Participants will: * Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis

Detailed description

This study will include the subjects of a series of studies on monogenic diabetes conducted by our team, including neonatal diabetes, maturity-onset diabetes of the young, maternally inherited diabetes and deafness, and other monogenic diabetes caused by different causative genes, and establish a large sample database and specimen bank through follow-up and omics analysis.

Interventions

OTHERNo Interventions

No Interventions

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age 2. Body mass index (BMI) at diagnosis 28 kg/m² 3. Negative glutamic acid decarboxylase antibody (GAD-Ab)

Exclusion criteria

1. Secondary diabetes 2. Active malignancy or history of malignant tumor within the past 5 years

Design outcomes

Primary

Measure	Time frame	Description
Screened and confirmed monogenic diabetes	6 months	Screened and confirmed through genetic testing according to established diagnostic criteria for monogenic forms of diabetes (including MODY, neonatal diabetes, and other monogenic subtypes)

Countries

China

Contacts

CONTACTMing Liu

mingliu@tmu.edu.cn+86 022-27813550

CONTACTHua Shu

shuhuawelcome@163.com+86 15010106182

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026